A phase II study of oral interferon-alpha (IFN-a) for patients with essential thrombocythemia or polycythemia vera.

被引：0
|
作者：
Quintas-Cardama, Alfonso [1 ]
Giles, Francis [1 ]
Cortes, Jorge [1 ]
Kantarjian, Hagop [1 ]
Verstovsek, Srdan [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4880
引用
收藏
页码：306B / 306B
页数：1
相关论文
共 50 条
  • [31] Association of monoclonal gammopathy and polycythemia vera or essential thrombocythemia: study of a large cohort of patients
    M. L. Randi
    T. Tison
    E. Ruzzon
    E. Pacquola
    A. Girolami
    [J]. Annals of Hematology, 2003, 82 : 214 - 217
  • [32] Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trials
    Silver, Richard T.
    Hasselbalch, Hans Carl
    [J]. HEMATOLOGY, 2016, 21 (07) : 387 - 391
  • [33] A PROSPECTIVE COMPARISON BETWEEN TREATMENT WITH PHLEBOTOMY ALONE AND WITH INTERFERON-ALPHA IN PATIENTS WITH POLYCYTHEMIA-VERA
    SACCHI, S
    LEONI, P
    LIBERATI, M
    RICCARDI, A
    TABILIO, A
    TARTONI, P
    MESSORA, C
    VECCHI, A
    BENSI, L
    RUPOLI, S
    UCCI, G
    FALZETTI, F
    GRIGNANI, F
    MARTELLI, MF
    [J]. ANNALS OF HEMATOLOGY, 1994, 68 (05) : 247 - 250
  • [34] Interferon alpha therapy for patients with essential thrombocythemia: Final results of phase II study initiated in 1986.
    Saba, R
    Jwied, M
    Quintas-Cardama, A
    Talpaz, M
    Giles, F
    Cortes, J
    Keating, M
    Estey, E
    O'Brien, S
    Garcia-Manero, G
    Kantarjian, H
    Freireich, EJ
    Verstovsek, S
    [J]. BLOOD, 2003, 102 (11) : 146A - 146A
  • [35] Phase II study of interferon-alpha (IFN), Gleevec or Iressa patients with metastatic renal cell carcinoma.
    Amato, R
    Kareidy, M
    Marsh, L
    Truong, L
    Shen, S
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9030S - 9030S
  • [36] THE ROLE OF ALPHA-INTERFERON IN ESSENTIAL THROMBOCYTHEMIA, POLYCYTHEMIA-VERA AND MYELOFIBROSIS WITH MYELOID METAPLASIA (MMM) - A CONCISE UPDATE
    SACCHI, S
    [J]. LEUKEMIA & LYMPHOMA, 1995, 19 (1-2) : 13 - 20
  • [37] Long Term Results of Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocythemia and Polycythemia Vera: Median Follow-up of 15 Years
    Masarova, Lucia
    Bose, Prithviraj
    Pemmaraju, Naveen
    Richie, Mary Ann
    Borthakur, Gautam
    Estrov, Zeev E.
    Kantarjian, Hagop
    Patel, Keyur P.
    Verstovsek, Srdan
    [J]. BLOOD, 2022, 140 : 9683 - 9684
  • [38] Treatment with pegylated Interferon-Atfa-2A (PEG-IFN-Aα-2A; PEGASYS™) for patients with essential thrombocythemia (ET) and polycythemia vera (PV).
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop
    Giles, Francis
    Cortes, Jorge
    Richie, Mary Ann
    Borthakur, Gautam
    Verstovsek, Srdan
    [J]. BLOOD, 2006, 108 (11) : 307B - 307B
  • [39] MORPHOMETRIC STUDY OF THE BONE-MARROW IN POLYCYTHEMIA-VERA FOLLOWING INTERFERON-ALPHA THERAPY
    FRANCO, V
    FLORENA, AM
    ARAGONA, F
    CAMPESI, G
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 1993, 189 (01) : 52 - 57
  • [40] Pegylated interferon alfa-2a is effective and decreases LDH levels in patients with essential thrombocythemia and polycythemia vera
    Ekinci, O.
    [J]. LEUKEMIA RESEARCH, 2019, 85 : S27 - S27
12345